Skip to content

Less Infections for the Diabetic Foot

Randomized Study Comparing Different Durations of Antibiotic Treatment for Diabetic Foot Infections

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03615807
Enrollment
182
Registered
2018-08-06
Start date
2017-02-16
Completion date
2020-03-31
Last updated
2020-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot

Keywords

diabetic foot infections, antibiotic reduction, osteomyelitis, soft tissue infections

Brief summary

This is a randomized, unblinded, single-centre study. After eventual surgical debridement (not amputation), patients will be randomized to receive 1 of 2 targeted antibiotic regimens, in the ratio 1:1. For diabetic toe osteomyelitis, the patients will be randomized between a 3 and a 6 week's arm, for soft tissue infections between 10 and 20 days. The final assessments used in the primary efficacy analysis will be obtained at the test-of-cure (TOC) visit approximately 60 days after treatment is stopped.

Detailed description

Diabetic foot infections (DFI) are frequent and are associated with a high burden of morbidity, costs, recurrence risk or new episodes of infections. About two-third of recurrent DFI may reveal other microorganisms than in the previous period, suggesting new episodes of infection due to the underlying problem, and/or selection by prior antimicrobial therapy. Osteomyelitis in the diabetic toe is almost always established by contiguous spread of infection from a chronic ulcer. It occurs in up to 15% of patients with a diabetic foot ulcer and about 20% of all DFI (and over half of severe infections) involve bone at presentation. The severity of a diabetic foot infection is based on the local and systemic signs and symptoms of infection and has been categorically defined in the Infectious Disease Society of America guidelines for the Diagnosis and Treatment of Diabetic Foot Infections (IDSA guidelines). Knowing the potential for poor outcomes, many clinicians have tended to treat DFIs with a long duration of antibiotic therapy, with many side effects, development and spreading of antibiotic resistance, and associated costs. Data from recent comparative trials has shown that 1-2 weeks is sufficient for most soft tissue infections, and 4 to 6 weeks appears adequate in those with (unresected) infected bone. Retrospective reviews over the past two decades have demonstrated that about two-thirds of selected patients with diabetic foot osteomyelitis can achieve remission with antibiotic therapy alone (i.e., without bone resection). One recent randomized trial found that treatment with only antibiotic therapy (given for 90 days) gave similar clinical outcomes to treatment with conservative surgery (removal only of the infected bone) along with just a short course of antibiotic therapy. Another randomized trial compared a 6-week against 12-week course of antibiotic therapy, without concomitant surgery, for diabetic foot osteomyelitis and also found similar outcomes. Likewise, the optimal antibiotic duration for any skin and soft tissue infection is unknown. According to some databases of University of Geneva Hospitals, among 378 skin and soft tissue infections in 346, overall cure was achieved in 330 episodes (87%) after a median antibiotic administration of 15 days. In multivariate Cox regression analysis, duration of antibiotic therapy (HR 1.0, 95%CI 0.96-1.02) did not influence treatment failure among patients with positive MRSA carriage. Our study intends to optimize the duration of antibiotic therapy in DFI; for skin and soft tissue infections as well as for diabetic toe osteomyelitis that is not amputated.

Interventions

PROCEDURESurgical debridement (if needed)

Surgical debridement

Microbiological sampling

PROCEDURERevascularisation (if needed).

Revascularisation (if needed).

Off-loading by Special shoes

BEHAVIORALPatient's education and instructions

Patient's education and instructions by specialized nurses

Regular wound debridement by specialized nurses

Systemic antibiotic duration according to the study arms

Sponsors

University Hospital, Geneva
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Two prospected-randomized protocols

Eligibility

Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18 2. Diabetes mellitus 3. Diabetic Foot Infections 4. Surgical intervention to remove all necrotic tissue or tenotomy. 5. Osteomyelitis limited to bone contact or cortical lesions in X-ray.

Exclusion criteria

1. Implanted device. 2. More than 96 hours of systemic antibiotic therapy prior to inclusion 3. Amputation 4. Destructive osteomyelitis 5. Concomitant infections requiring more than 14 days of antibiotic therapy.

Design outcomes

Primary

MeasureTime frameDescription
Number of Participants Experiencing Clinical Failure30-60 daysVisual and dichotomous evaluation regarding the numbers of clinical recurrence/failure

Secondary

MeasureTime frameDescription
Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy30-60 daysAdverse events related to the antibiotic therapy.

Countries

Switzerland

Participant flow

Participants by arm

ArmCount
Short Antibiotic Arm
10 days for soft tissue infections 3 weeks for osteomyelitis Surgical debridement (if needed): Surgical debridement Microbiological sampling: Microbiological sampling Revascularisation (if needed).: Revascularisation (if needed). Off-loading: Off-loading by Special shoes Patient's education and instructions: Patient's education and instructions by specialized nurses Wound debridement: Regular wound debridement by specialized nurses Antibiotic duration: Systemic antibiotic duration according to the study arms
79
Standard Antibiotic Arm
20 days for soft tissue infections 6 weeks for osteomyelitis Surgical debridement (if needed): Surgical debridement Microbiological sampling: Microbiological sampling Revascularisation (if needed).: Revascularisation (if needed). Off-loading: Off-loading by Special shoes Patient's education and instructions: Patient's education and instructions by specialized nurses Wound debridement: Regular wound debridement by specialized nurses Antibiotic duration: Systemic antibiotic duration according to the study arms
80
Total159

Baseline characteristics

CharacteristicTotalStandard Antibiotic ArmShort Antibiotic Arm
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
94 Participants42 Participants52 Participants
Age, Categorical
Between 18 and 65 years
65 Participants38 Participants27 Participants
Age, Continuous68 years67 years70 years
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
159 Participants80 Participants79 Participants
Region of Enrollment
Switzerland
159 participants80 participants79 participants
Sex: Female, Male
Female
17 Participants8 Participants9 Participants
Sex: Female, Male
Male
142 Participants72 Participants70 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 790 / 80
other
Total, other adverse events
5 / 796 / 80
serious
Total, serious adverse events
5 / 796 / 80

Outcome results

Primary

Number of Participants Experiencing Clinical Failure

Visual and dichotomous evaluation regarding the numbers of clinical recurrence/failure

Time frame: 30-60 days

ArmMeasureValue (NUMBER)
Short Antibiotic ArmNumber of Participants Experiencing Clinical Failure26 Participants
Long Antibiotic ArmNumber of Participants Experiencing Clinical Failure30 Participants
Secondary

Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy

Adverse events related to the antibiotic therapy.

Time frame: 30-60 days

ArmMeasureValue (NUMBER)
Short Antibiotic ArmNumber of Participants Experiencing Adverse Events Related to the Antibiotic Therapy31 Participants
Long Antibiotic ArmNumber of Participants Experiencing Adverse Events Related to the Antibiotic Therapy27 Participants

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026